The Priority Review acceptance and absence of an advisory committee meeting reduce regulatory risk and increase the probability of approval by the March 10, 2027 PDUFA date. Traders should monitor for any FDA briefing documents or AdCom announcements, though none are currently planned. The compelling Phase 3 efficacy and safety data support a favorable risk/reward profile into the PDUFA catalyst.
Price Chart
Executive Summary
Intellia Therapeutics announced FDA acceptance of its Biologics License Application (BLA) for lonvoguran ziclumeran (lonvo-z) for hereditary angioedema (HAE) with Priority Review and a PDUFA target action date of March 10, 2027. The FDA also advised it is not currently planning to hold an advisory committee meeting. If approved, lonvo-z would be the first in vivo CRISPR-based therapy and the only one-time HAE treatment, supported by Phase 3 data showing an 87% reduction in monthly attacks and 62% of patients attack-free for six months.
Key Facts
- FDA accepted BLA for lonvo-z with Priority Review; PDUFA date set for March 10, 2027
- FDA not currently planning to hold an advisory committee for the application
- Phase 3 HAELO trial met primary endpoint: 87% reduction (p<0.0001) in mean monthly attacks vs placebo
- 62% of lonvo-z patients were entirely attack-free and HAE therapy-free for six months vs 11% placebo (p<0.0001)
- No serious adverse events observed in the lonvo-z arm; all TEAEs were mild or moderate
- If approved, lonvo-z would be the world's first in vivo CRISPR-based therapy and only one-time HAE treatment
Financial Impact
No financial figures provided in the filing; potential commercial value of a first-in-class one-time HAE therapy is significant but unquantified
Risk Factors
- FDA could still issue a Complete Response Letter (CRL) or require additional data before approval
- Commercial launch execution risk if approved, including manufacturing scale-up and market access
- Potential competition from existing HAE therapies and other pipeline candidates
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-385194 |
| Document: ntla-ex99_1.htm | 0001193125-26-385194 |
| Document: 0001193125-26-385194-index-headers.html | 0001193125-26-385194 |
| Document: 0001193125-26-385194-index.html | 0001193125-26-385194 |
| Document: 0001193125-26-385194.txt | 0001193125-26-385194 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 2, 2026 23d ago | Press Release | $12.75 $12.58 | ▼ −1.33% | ▼ −1.76% | $11.23 (−11.92%) |
Sep 8, 2026 6w ago | 8-K | $12.21 $11.60 | ▼ −5.00% | ▼ −4.66% | $11.23 (−8.03%) |
Aug 6, 2026 11w ago | 8-K | $11.24 $11.83 | ▲ +5.25% | ▲ +4.04% | $11.23 (−0.09%) |
Jun 15, 2026 19w ago | 8-K | $14.92 $15.75 | ▲ +5.56% | ▲ +6.95% | $11.23 (−24.73%) |
Jun 13, 2026 19w ago | Press Release | $14.92 $15.75 | ▲ +5.56% | ▲ +6.95% | $11.23 (−24.73%) |
Jun 1, 2026 21w ago | Press Release | $13.73 $13.54 | ▼ −1.38% | ▲ +1.37% | $11.23 (−18.21%) |
May 11, 2026 24w ago | 8-K | $14.42 $12.69 | ▼ −12.00% | ▼ −11.91% | $11.23 (−22.12%) |
Apr 27, 2026 25w ago | Press Release | $13.20 $13.87 | ▼ −5.08% | ▼ −3.38% | $11.23 (+14.92%) |
Apr 27, 2026 26w ago | 8-K | $13.04 $13.87 | ▲ +6.37% | ▲ +5.96% | $11.23 (−13.88%) |
Apr 3, 2026 29w ago | Press Release | $13.30 $14.26 | ▲ +7.22% | ▲ +3.08% | $11.23 (−15.56%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers